Date: Thursday 29 Sep 2011
Proximagen group, a consolidator in the central nervous system (CNS) treatments sector, and Lundbeck have entered into a strategic partnership with the aim of formalizing a tie-up between the two companies.
| Proximagen progresses while conserving cash | 23-Mar-2011 | ShareCast |
| SABMiller non-exec tops up | 19-Jan-2011 | ShareCast |
| Small caps round-up: Forte Energy, Discovery Met... | 21-Dec-2010 | ShareCast |
| Michael Page executives raise £7.8m | 21-Oct-2010 | ShareCast |
| Directors buy following Proximagen deal | 05-Aug-2010 | ShareCast |
| Appointment of Nominated Adviser and Broker | 23-May-2012 | 07:00 | RNS |
| Result of Annual General Meeting | 15-May-2012 | 15:25 | RNS |
| REPLACEMENT: Proximagen welcomes positive vote | 11-May-2012 | 13:01 | RNS-R |
| Proximagen welcomes positive vote on lorcaserin | 11-May-2012 | 11:25 | RNS-R |
| Statement re PRX Annual Report and Accounts | 16-Apr-2012 | 07:00 | RNS |
No recent information was found.
| Investment Column:Proximagen Neuroscience | 25-Mar-2009 | The Independent |
| Market Report: Xstrata fired up by talk of Anglo... | 08-Dec-2007 | The Independent |
| Miners dig deep as shares rise on M&A speculation | 08-Dec-2007 | The Scotsman |
| BG Group fired up as market rebounds in style | 01-Aug-2007 | The Independent |
| Small caps | 01-Aug-2007 | Times |
| Protox Therapeutics Retains Leading Investor Rel... | 23-Jun-2006 | Market Wire |
| Protox Announces Changes to Board of Directors | 20-Jun-2006 | Market Wire |
Proximagen Neuroscience plc (AIM: P... |
05-Jun-2009 | Proactive Investors |
| Yesterday's trading: 'Daddy hedge' king of bears | 15-Jul-2008 | This Is Money |
| Market report: Wednesday close | 29-Aug-2007 | This Is Money |
| Newspaper and magazine share tips | 19-Jun-2007 | This Is Money |
| Currency | UK Pounds |
| Share Price | 265.00p |
| Change Today | 0.000p |
| % Change | 0.00 % |
| 52 Week High | 278.50p |
| 52 Week Low | 114.00p |
| Volume | 0 |
| Shares Issued | 63.12m |
| Market Cap | £167.27m |
| Beta | 0.11 |
| RiskGrade | 310 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Finance Director | James Douglas Hunter |
| CEO | Kenneth Mulvany |
You are here: research